Biological Perspectives: Ketamine as an Alternative Treatment for Treatment-Resistant Depression Biological Perspectives: Ketamine as an Alternative Treatment for Treatment-Resistant Depression

Perspectives in Psychiatric Care

Volumn 49, Issue 1, 2013, Pages 2-4

  Dowben, Jonathan S ^a   Grant, Joan S ^a   Keltner, Norman L ^a  

^a NONE

Author keywords

Ketamine; Major depression; Treatment resistant depression

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

BIPOLAR DISORDER; BRAIN; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR DEPRESSION; NURSING; REVIEW; SYNAPSE; SYNAPTIC TRANSMISSION; TREATMENT RESISTANT DEPRESSION; ANTAGONISTS AND INHIBITORS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG EFFECTS;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; BRAIN; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84872161008     PISSN: 00315990     EISSN: 17446163     Source Type: Journal    
DOI: 10.1111/ppc.12006     Document Type: Note

References (15)

1. Aan het Rot, M., Charney, D. S., & Mathew, S. J. (2008). Intravenous ketamine for treatment-resistant major depressive disorder. Primary Psychiatry, 15(4), 39-47.
2. Aan het Rot, M., Zarate, C. A., Jr., Charney, D. S., & Mathew, S. J. (2012). Ketamine for depression: Where do we go from here? Biological Psychiatry, 72, 537-547. doi: 10.1016/J.biopsych.2012.05.003.
3. Anand, A., & Mathew, S. J. (2011). Ketamine treatment for major depression. Psychopharm Review, 46(12), 89-96. doi: 10.1097/01.PSYPHR.00004101.33.47951.30.
4. Duman, R. S., & Li, N. (2012). A neurotrophic hypothesis of depression: Role of synaptogenesis in the actions of NMDA receptor antagonists. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 367, 2475-2484.
5. Duman, R. S., Li, N., Liu, R. J., Duric, V., & Aghajanian, G. (2012). Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology, 62(1), 35-41. doi: 10.1008/rstb.2011.0357.
6. IMS Health Midas. (December 2011). Top 20 global therapeutic classes, 2011 total audited markets. Retrieved September 23, 2012, from http://www.imshealth.com/ims/Global/Content/Corporate/Press%20Room/Top-line%20Market%20Data/2010%20Top-line%20Market%20Data/Top_20_Global_Therapy_Classes.pdf.
7. IMS Institute for Healthcare Informatics. (April 2012). The use of medicines in the United States: Review of 2011. Retrieved September 23, 2012, from http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf.
8. Kuhn, R. (1958). The treatment of depressive states with G-22355 (imipramine hydrochloride). American Journal of Psychiatry, 115, 459-464.
9. Machado-Vieira, R., Salvadore, G., DiazGranados, N., & Zarate, C. A. (2009). Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacological Therapy, 123(2), 143-150. doi: 10.1016/j.pharmthera.2009.02.010.
10. Messer, M. M., & Haller, I. V. (2010). Maintenance ketamine treatment produces long-term recovery from depression. Primary Psychiatry, 17(4), 48-50.
11. Murrough, J. W. (2012). Ketamine as a novel antidepressant: From synapse to behavior. Clinical Pharmacology and Therapeutics, 91, 303-309. doi: 10.1038/clpt.2011.244.
12. Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., Aan het Rot, M., Iosifescu, D. V. (July 26, 2012). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry. [Epub ahead of print].
13. Nasrallah, H. A. (2012). Innovative approaches to treatment-resistant depression. Current Psychiatry, 11(6), 4-5.
14. Rush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., Wisniewski, S. R. (2011). Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. American Journal of Psychiatry, 168(7), 689-701. doi: 10.1176/spp1.ajp.2011.10111645.
15. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917.